8-KOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Mar 3, 2021)

Filed March 3, 2021For Securities:BSX

Summary

Boston Scientific Corporation (BSX) announced on March 3, 2021, a significant strategic acquisition: the definitive agreement to purchase Lumenis LTD.'s global Surgical business unit. This acquisition, for an upfront cash payment of $1.07 billion, will expand BSX's portfolio with innovative laser systems and fibers primarily for urology and otolaryngology procedures. The transaction is expected to close in the second half of 2021, subject to customary closing conditions. Lumenis will retain its Aesthetics and Ophthalmology business units, which will be separated into a new entity prior to the acquisition's completion. This move signals BSX's intent to strengthen its position in key surgical specialties and drive future growth through targeted inorganic expansion.

Key Highlights

  • 1Boston Scientific to acquire Lumenis' global Surgical business unit for $1.07 billion in cash.
  • 2Acquisition focuses on energy-based medical solutions, specifically laser systems and fibers for urology and otolaryngology.
  • 3Transaction is expected to close in the second half of 2021, subject to customary conditions.
  • 4Lumenis' Aesthetics and Ophthalmology businesses will be separated before the acquisition closes.
  • 5This is a strategic move to enhance Boston Scientific's surgical portfolio and market presence.
  • 6The filing includes a press release detailing the acquisition and a cautionary statement regarding forward-looking information.

Frequently Asked Questions

The primary financial impact is the commitment of $1.07 billion in cash for the acquisition of Lumenis' Surgical business. Investors should monitor future filings for details on how this acquisition will be financed and its expected contribution to revenue and profitability.

Boston Scientific will acquire Lumenis' global Surgical business unit, which specializes in energy-based medical solutions, including innovative laser systems and fibers. These products are primarily used in urology and otolaryngology procedures.

The company anticipates completing the acquisition in the second half of 2021, provided that all customary closing conditions are met.

No, Boston Scientific will only acquire Lumenis' global Surgical business unit. Lumenis plans to separate its Aesthetics and Ophthalmology business units into a new entity before the acquisition is finalized.